Oncoscience GmbH

Oncoscience AG has withdrawn its application to the EMEAfor marketing authorisation of the EGFR-targeted drug nimotuzumab for the treatment of paediatric glioma (brain cancer), saying that it was not

YM BioSciences' experimental EGFR-targeted humanised monoclonal antibody drug nimotuzumab (YMB1000-015) will not progress to a pivotal trial in colorectal cancer at this time, but the Canadian company

Late-stage venture capital deals are on the rise. Four VCs explain how and why they invest here. by Mary Stuart In recent years, venture capitalists who once only invested in biotech have been increas

Acquisitions Astex merges with metaGen in all-stock deal Astex Technology Ltd. (Cambridge, UK) metaGen Pharmaceuticals GMBH (Berlin, Germany) metaGen Pharmaceuticals GMBH (genomics-based technolog